Maplight Therapeutics, Inc. (NASDAQ:MPLT) Given Average Recommendation of “Moderate Buy” by Brokerages

Shares of Maplight Therapeutics, Inc. (NASDAQ:MPLT) have earned a consensus recommendation of “Moderate Buy” from the eleven research firms that are presently covering the firm, MarketBeat.com reports. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating, seven have assigned a buy rating and two have issued a strong buy rating on the company. The average 12 month target price among analysts that have covered the stock in the last year is $34.4286.

MPLT has been the topic of a number of analyst reports. Wall Street Zen cut Maplight Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, March 21st. TD Cowen initiated coverage on Maplight Therapeutics in a report on Tuesday, April 7th. They set a “buy” rating on the stock. Weiss Ratings initiated coverage on Maplight Therapeutics in a report on Thursday, January 22nd. They set a “sell (e)” rating on the stock. Needham & Company LLC initiated coverage on Maplight Therapeutics in a report on Wednesday, April 8th. They set a “buy” rating and a $37.00 target price on the stock. Finally, HC Wainwright initiated coverage on Maplight Therapeutics in a report on Monday, May 4th. They set a “buy” rating and a $45.00 target price on the stock.

Maplight Therapeutics Trading Down 1.9%

Shares of Maplight Therapeutics stock opened at $28.73 on Friday. Maplight Therapeutics has a 12-month low of $12.24 and a 12-month high of $33.28. The company has a market cap of $1.22 billion and a PE ratio of -0.72. The business’s 50 day moving average is $24.24.

Maplight Therapeutics (NASDAQ:MPLT) last announced its quarterly earnings data on Thursday, May 14th. The company reported ($1.34) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.91) by ($0.43). Analysts forecast that Maplight Therapeutics will post -3.96 earnings per share for the current fiscal year.

Insider Buying and Selling at Maplight Therapeutics

In related news, insider James Woodruff Lillie sold 24,811 shares of the business’s stock in a transaction that occurred on Wednesday, May 6th. The stock was sold at an average price of $28.76, for a total transaction of $713,564.36. Following the transaction, the insider directly owned 243,450 shares of the company’s stock, valued at approximately $7,001,622. The trade was a 9.25% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Anatol Kreitzer sold 45,422 shares of the business’s stock in a transaction that occurred on Monday, April 27th. The stock was sold at an average price of $29.66, for a total value of $1,347,216.52. Following the transaction, the insider directly owned 211,190 shares in the company, valued at $6,263,895.40. The trade was a 17.70% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last three months, insiders acquired 25,000 shares of company stock worth $441,168 and sold 391,204 shares worth $11,125,068. 3.80% of the stock is owned by insiders.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Oxford Asset Management LLP acquired a new position in Maplight Therapeutics in the 4th quarter valued at $312,000. Deutsche Bank AG acquired a new position in Maplight Therapeutics in the 4th quarter valued at $210,000. Walleye Capital LLC acquired a new stake in shares of Maplight Therapeutics during the 4th quarter worth $205,000. MetLife Investment Management LLC acquired a new stake in shares of Maplight Therapeutics during the 4th quarter worth $172,000. Finally, New York State Common Retirement Fund acquired a new stake in shares of Maplight Therapeutics during the 4th quarter worth $93,000.

About Maplight Therapeutics

We are a clinical-stage biopharmaceutical company focused on improving the lives of patients suffering from debilitating central nervous system, or CNS, disorders. We were founded by globally recognized leaders in psychiatry and neuroscience research to address the lack of circuit-specific pharmacotherapies available for patients. Our discovery platform holds the potential to fill this void by identifying neural circuits causally linked to disease and targeting those circuits for therapeutic modulation.